Bioscience Institute, Genomics and Clinic

The world’s leading Genomics and Regenerative Medicine Centres are based in Europe (Roma, Milano and San Marino) and Middle East (Dubai). Bioscience offer the most advanced personalized expanded adopse derived stem cell therapies and Next Generation Sequencing genomic test for solid cancer risk management. The premium service in Regenerative Medicine include cryopreservation and expansion of stem cells for personalized anti-aging treatments, aesthetic plastic surgery, hair regeneration and wound care. The Genomics premium services is based on Liquid Biopsy for the solid cancer risk assessment, early detection and monitoring of cancer targeted therapy. The services of Bioscience are unique in the world as they offer the most advanced autologous cell therapies and genetic profilling.

Excellence of Bioscience

All the procedures of cell extraction, expansion and therapy are carried out at laboratories of Bioscience Clinic - Middle East and Bioscience Institute that are located in Dubai Healthcare City (DHCC) and in San Marino. The development of the laboratories in Dubai have benefited from the 7 years’ experience of existing Bioscience Institute laboratories in Europe that are considered one of the most advanced in the world. Bioscience Clinic Laboratories are licensed and inspected by the Ministry of Health of UAE and DHCC who had also inspected laboratories of Bioscience Institute in Europe. The quality standards are compliant with Good Manufacturing Practice (GMP) and can be verified by anyone who visits the Bioscience Clinic website - www.bioinst.ae.
Together with laboratories situated in Europe, those of Dubai are the only ones in the world that provide the ability to check the standards of environmental and instrumental operating procedures online. Through the Bioscience Clinic website it is possible to view the internal cameras of the laboratories and to verify the procedures adopted by biologists. The parameters of the environmental quality and the performance of the instruments are recorded through a control system that is always visible on the website. The ethical principles of Bioscience Institute are expressed in this model of quality and transparency.

Bioscience Institute was founded in Republic of San Marino in 2006 with € 875,000.00 fully-paid capital. It is a compound of
● Regenerative Medicine Clinic including cell bank, cell factory and clinic dedicated to expanded adipose dervived stem cells therapies. Cell Factory is used for the storage and expansion of Umbilical Cord Blood Stem Cells, Adipose Derived Stem Cells, Fibroblasts, Keratinocytes, Melanocytes.

● Genomics Platform including the Circulating Free DNA, Curculating Tumor DNA and Circulating Tumor Cells detection for Solid Cancer Risk Management.
● Bioscience Institute, in partnership with leading Universities, performs the scientific research activity, aimed at extending the possible clinical applications of stem cells in different fields of medicine. The company owns and has an exclusive management of laboratories where its work is conducted. Since the first year of operation Bioscience Institute has certified all annual financial statements, as required by statute, by the auditors.

Bioscience Clinic Middle East has established a worldwide excellence facility in Dubai in 2014. It is the first Regenerative Medicine Clinic in the Middle East that offers the most advanced personalized autologous cell therapies.
Bioscience Clinic includes cell bank, cell factory and clinic dedicated to cell banking, culture and therapies.
Our Cell Factory is used for the storage and expansion of Adipose Derived Cells and Fibroblasts.
The Aesthetic and Anti-Aging services of Bioscience are unique in the world as they offer the most advanced autologous cell therapies.
The Group of Bioscience facilities works only at the highest level of excellence and includes cell banks, clean rooms and clinics.

All the procedures of biopsies, samples collection, cell extraction, expansion and grafts of cultured cells are carried out at our laboratories and clinic that are located in Dubai Healthcare City (DHCC). The development of the laboratories in Dubai has benefited from the 7 years’ experience of existing Bioscience Institute laboratories in Europe that are considered one of the most advanced in the world. Bioscience Clinic Laboratories are licensed and inspected by the Ministry of Health of UAE and DHCC who had also inspected laboratories of Bioscience Institute in Europe.

is a University spin off between with Roma Tor Vergata University and Bioscience Institute. Bioscience Genomics is the first company that perform the solid cancer risk management based on cfDNA, ctDNA, Germinal DNA and CTC analysis together, to healthy people and oncologic patients. Today the Liquid Biopsy is used only on patient with cancer already diagnosed (eg: for the understanding of the patient response to drug treatment). Having already three genomics platforms (Roma, Milano and San Marino) for liquid biopsy services based on circulating free DNA, circulating tumor DNA and Circulating Tumor Cells to perform the Solid Cancer Risk Management for the risk assessment based on genetic profiling, solid cancer early detection based on cfDNA and monitoring of therapies based on CTC and ctDNA.
PATENT
The Risk Assessment Program HELIXAFE is patent pending from Bioscience Institute.

Professor Manuel Salto-Tellez (MD-LMS, FRCPath, FRCPI) is the Chair of Molecular Pathology at Queen’s University Belfast, Clinical Director for Molecular Diagnostics for Northern Ireland and Deputy Director of the Centre for Cancer Research and Cell Biology.
By Sept 2016, Prof Salto-Tellez was author or co-author of more than 225 internationally peer-reviewed articles in translational science, molecular pathology and diagnostics, including work published in NEJM, Nature Medicine, Gastroenterology, FASEB, EMBO, Cancer Research and Clinical Cancer Research, among others. He has published a similar number of abstracts in international conferences, and is editor or contributor to some of the key textbooks of pathology and oncology.
Professor Salto-Tellez studied Medicine in Spain (Oviedo), Germany (Aachen) and The Netherlands (Leiden). He specialized in Histopathology in the UK (Edinburgh and London) and in Molecular Pathology in USA (Philadelphia). For more than 10 years he worked at the National University of Singapore and its National University Hospital, where he was associate professor, senior consultant, director of the Diagnostic Molecular Oncology Centre, Vice-dean for Research and senior scientist at the Cancer Research Institute.
Prof Salto-Tellez serves in the following committees: Colorectal Group of the UK National Cancer Research Institute; Molecular Pathology Committee of the Association of Clinical Pathology; Cancer Research UK Biomarker Expert Review Panel; NCRI CM-Path; UKNEQAS Committee for DNA Quality; Molecular Pathology Committee of Genomics England; Genomics England GCIPs on colorectal cancer and data interpretation; Wales Cancer Research Centre’s External Advisory Board (EAB); Cancer Research UK Experimental Medicine Expert review Panel; as well as ad-hoc committees and review panels with NIHR, NIH and others.
He is in the editorial board of the following journals: Journal of Clinical Pathology, Expert Opinion on Molecular Diagnostics, Cytopathology, Journal of Oncopathology and Pathogenesis.
He holds more than £5M in competitive grant funding.
Prof Salto-Tellez leads the Northern Ireland – Molecular Pathology Laboratory (NI-MPL). This is a hybrid laboratory that is CPA accredited to take care of the molecular diagnostics of the whole of NI (population = 1.8 million) and, at the same time, support the translational research mission of the Centre for Cancer Research and Cell Biology.

Giuseppee Novelli is Head of the Human Genetics Research Unit at The Tor Vergata University of Rome (Italy) and Dean of the Medical School in the same University. He graduated with a BSc in Biology from Urbino University in 1981 and achieved his PhD in Medical Genetics at the Sapienza University of Rome in 1985.
Since 1981, Professor Novelli has collaborated with Unité de Recherches de Biologie Prénatale INSERM U.73, Paris (France), Groupe de Génétique Moléculaire INSERM U.91 Créteil (France), the University ofSouthern California (Los Angeles, USA) and the Catholic University of Rome.
Professor Novelli is member of the National Committee on Cloning (Italian Ministry of Health) consultant to the Criminal Police Division of Science and DNA analysis, Rome; member of the National Committee (Italian Ministry of Research) in Molecular Genetics; consultant to GlaxoWellcome (Verona, Italy); Reviewer of INSERM (France) for scientific projects; member of the National Committee of Cell Stem Research (Italian Ministry of Health); member of the National Committee of Post-Genomic Project (Italian Ministry of Research); director of the Laboratory of Medical Genetics, Tor Vergata Hospital School; member of OECD (Organisation for Economic Co-Operation and Development); member of National Committee Biotechnology, President of Italian Ministry; member of National Committee on Genetic Testing; member of the «GROUPE D’EXPERTS EN GENETIQUE MOLECULAIRE» Maladies neurologiques, musculaires, neuro-sensorielles et retards mentaux. Ministère de la santé, de la famille et des personnes handicapées (France). He’s also reviewer of many international journals and a member of the American Society of Human Genetics (USA); the European Society of Human Genetics (ESHG); the American Association for the Advancement of Science (USA); the Human Genome Organization (HUGO); the Italian Society of Human Genetics (SIGU); and the World Muscle Society (WMS). He is member of Pharmacogenetics Working Party (PgWP), the CHMP Expert Group on Pharmacogenetics for EMA (European Medicines Agency).

Prof. Mario Roselli Biosketch
Mario Roselli received his M.D. in 1983. Specialist in Oncology (1986) and in Nuclear Medicine (1992), he is currently Head of Medical Oncology of the University Hospital Tor Vergata and Associated Professor in Medical Oncology at the Department of Systems Medicine, School of Medicine University of Rome "Tor Vergata", Italy.
Prof. Roselli is presently member of the Tor Vergata Institutional Review Board (IRB) and participates as Principal Investigator (PI) and/or co-investigator to several clinical projects, sponsored and granted either by Government Institutions or private Companies.
Among the funded projects of which Dr. Roselli has been PI, the "MCC - Medical Care Continuity" sponsored by the European Community (2004-2008) is of great interest in the context of the aims and mission pursued in the “continuous care trial” established in the Medical Oncology ward he directs. The project, aimed at establishing a telemedicine network between various European countries (France, Belgium, Italy and Poland) to ensure the continuity of care of cancer outpatients receiving active chemotherapy.
Following this experience, in 2009, as the Chief of the Medical Oncology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Prof. Roselli established a collaboration agreement with the San Raffaele Palliative Care Centers. Over this period, an interdisciplinary team has been refined to provide integrated oncologic, medical, and supportive care services for patients with cancer disease and their families, from diagnosis to palliative care.
This has been qualified by an ISO 9001-2008 certificate. The entire project has also been rewarded in 2012 and in 2015 with the certificate award for “designated centers of integrated oncology and palliative care by the European Society for Medical Oncology” (www.esmo.org). Prof. Roselli has been also actively involved in clinical and translational studies which have lead to the publication of 198 publications in international peer journals with a total impact factor equal to 712 and an H-Index of 31.
As part of an active collaboration with the Laboratory of Tumor Immunology and Biology of the National Cancer Institute, National Institutes of Health, Bethesda, MD, USA, Prof. Roselli has been involved in the investigation of novel strategies for cancer vaccines, such as the characterization of the T-box transcription factor Brachyury as a driver of epithelial-to-mesenchimal transition in human carcinoma cells, aiming to the development of Brachyury-based immunotherapeutic approaches for the treatment of cancer.

Dr Luca Quagliata - Activities Summary and Profile
Molecular Diagnostics Leader
Institute of Medical Genetics and Pathology, University Hospital of Basel
Since September 2015, I am responsible for coordinating the molecular-based diagnostic (e.g. high throughput sequencing analysis) and research laboratory activities performed at the Institute of Medical Genetics and Pathology of the University Hospital in Basel, Switzerland.
My Team has been among the first in Europe to introduce Next Generation Sequencing (NGS) in routine molecular diagnostics (e.g. analysis of Liquid Biopsy) with the ultimate goal of enabling Precision Medicine in Oncology. With a workload of about 3000 samples per year, we are nowadays a leading NGS provider for molecular genetics and pathology services in Switzerland and Europe.
Moreover, we also offer our assistance for molecularly informed prospective clinical trials (in collaboration with the Swiss Group for Clinical Cancer Research -SAKK-) and support translational medicine research projects within our Institution and for external collaborations. Finally, we conduct on a regular base large retrospective exploratory or validation studies taking advantage of our Biobank of human tissue (currently we have on going collaborations with the Novartis Group, Roche, Astra Zeneca and Thermo Fisher Scientific). The Institute of Medical Genetics and Pathology Biobank currently includes about 32.000 highly curated (with extensive clinical-pathological information) Fresh-Frozen (FF) and corresponding Formalin-Fixed-Paraffin-Embedded (FFPE) samples.
Representing a unique hotspot of experts and resources, beside my diagnostic duty with more than a 1000 signed off cases within the last two years, my Institution still allows me to conduct high-level translational research activity. Carried out in collaboration with the Molecular Pathology Research Group (lead by Prof L Terracciano), my research interest is concentrating on the identification and functional characterization of lncRNAs (long non-coding RNAs) as well the study of tumor heterogeneity in cancer, with a special focus in Hepatocellular Carcinoma (HCC).

Nicola Aceto is a Swiss National Science Foundation Assistant Professor of Oncology and Group Leader of the Cancer Metastasis laboratory at the University of Basel, Switzerland. Previously, he trained at Harvard Medical School and Massachusetts General Hospital in Boston, at the Broad Institute of MIT and Harvard in Cambridge, and at the Friedrich Miescher Institute in Basel.
He has authored several high-impact peer-reviewed publications in leading journals in the oncology field, and he is an inventor on 4 patents related to the diagnosis and treatment of cancer. His major discovery has been the identification of circulating tumor cell clusters in the blood of patients with cancer, highlighting a previously unappreciated and potentially targetable mechanism of how cancer cells metastasize.
Dr. Aceto is the recipient of several prestigious awards, including an honorable mention within the Wachtel Cancer Research Award from the American Association for the Advancement of Science, an abstract award from Harvard Medical School, an ERC starting grant from the European Union, and a Professorship from the Swiss National Science Foundation.
He has been an invited speaker in a number of congresses and organizations, including the University of California Berkeley, Google[x] Life Sciences, the Novartis Institute for Biomedical Research, and the World Circulating Tumor Cell Summit.

During the last 10 years I focused my research in the understanding of how the selective pressure imposed by anti-HER2 agents and PI3K inhibitors modifies the evolution of drug resistance in breast cancer. I developed expertise in the field while I was running Dr. Jose Baselga’s laboratory in Barcelona (Vall d’Hebron Hospital, Spain) and in Boston (Massachusetts General Hospital). During this time I discovered that truncated forms of HER2; lacking the extracellular domain, limit the activity of the FDA-approved anti-HER2 antibody trastuzumab. Moreover, I found that amplification and/or overexpression of cyclin E negatively correlates with clinical response to trastuzumab-based therapy.
Concurrently, I proposed new therapeutic strategies to overcome or delay the emergence of such resistance. One example is the dual HER2 blockade using trastuzumab and lapatinib in combination, resulted to be superior compared to single agent both in preclinical models and in the clinical setting. More recently, we showed that dual mTOR inhibition in combination with lapatinib is capable to counteract lapatinib-resistant tumors. Moreover, we discovered that, among the HER2 positive tumors, there is a subset that is more dependent on HER2 for survival and is exquisitely sensitive to anti-HER2 therapy.
In the field of PI3K inhibitors I proposed that PI3K blockade in combination with PARP inhibition in triple negative breast cancer models or with mTORC1 inhibitors in PIK3CA-mutant models results in synergistic antitumor activity. Moreover, I contributed in the discovery that sustained mTOR activity can limit the efficacy of PI3K-alpha specific inhibitors in breast cancer. More recently, I demonstrated that progressive loss of PTEN leads to acquired resistance to PI3Kα specific inhibition in breast cancer and that simultaneous blockade of EGFR, HER3 and the PI3K-AKT pathway is an effective therapeutic strategy in triple negative breast cancer. The majority of my laboratory findings provided (or are providing) important insights for the design of new clinical trials testing the efficacy of these targeted therapies in breast cancer.
In summary, I believe that my experience in assessing PI3K signaling, evaluating PI3K inhibitors in pre-clinical studies, and discovering resistance mechanisms to targeted therapies positions me well to execute the proposed studies in this application.


Partner


ETHICS

The field in which Bioscience is active is marked by clear international laws and guidelines, which range from being very strict or very tolerant. This passes responsibility for self-control on the individual company, whose role is to guarantee the respect of ethical principles, even when they are not imposed by law. In this context, Bioscience places ethics and knowledge at the heart of its operations and adheres to the most rigorous quality control standards.

KNOWLEDGE

Daily meta-disciplinary research has allowed Bioscience to develop a large knowledge bank that is a consequence of the translation of scientific results to the different specialized compartments. This model overcomes the harmful closures towards meta-disciplinary research that are sometimes reducing the perspective of research groups.

CHALLENGE

Bioscience Institute’s vision is based on the idea that invasive surgery and chemistry can be partially replaced by cell biology and genomics. Science already uses autologous cells as a therapeutic and corrective agent and biology is ready to take the ‘first slices’ of the market away from chemistry. Correction of genetic defects detected during prenatal development is possible by means of carriers that can rescue the defect, restoring a genetically normal condition. Bioscience Institute creates platforms, that aim to provide cell therapies and genomics services. This focus on knowledge puts Bioscience Institute in an advantageous competitive position as a leader in the market of Adipose Derived Stem Cells therapies and genomics.

Bioscience entrepreneurial Model

The company’s rapid growth has allowed it to overcome competitors and is mirrored by its commitment to offer cell therapy services and genetic testing largely supported by scientific evidences for safety and efficacy. The management model is also another contributing factor to Bioscience’s fast development. It is characterized by a hybrid solution between a foundation and a company. Over the course of the years, the company has reinvested all of its profits into research and development activities, keeping a low commercial profile. In this way, Bioscience was able to instigate important scientific collaborations with leading Universities who were developing pioneering procedures and methods around the clinical applications of cell products.

Know how

The company’s rapid growth has allowed it to overcome competitors and is mirrored by its commitment to offer cell therapy services and genetic testing largely supported by scientific evidences for safety and efficacy. The management model is also another contributing factor to Bioscience’s fast development. It is characterized by a hybrid solution between a foundation and a company. Over the course of the years, the company has reinvested all of its profits into research and development activities, keeping a low commercial profile. In this way, Bioscience was able to instigate important scientific collaborations with leading Universities who were developing pioneering procedures and methods around the clinical applications of cell products.


Publication

Gene Therapy

Gene Therapy is based on the introduction of genetic material into normal cells in order to counteract the effect of a disease gene or introduce a new function.
The early genetic diagnosis with G-Test allows an immediate intervention of Gene Therapy at birth, that has not been previously available.
The integration of the Bioscience platform of cell factory with that of genomics allows the production of GENE THERAPY.

Cancer Targeted Stem Cell Therapies

Cancer treatments are based on the combination of the identification of cancer genetic markers and of the administration of mesenchymal stem cells, in order to develop antitumour agents that robustly target cancerous cells while sparing normal cells.
These therapies involve the administration of MSC, as a drug or as a cell-based vehicle for cancer drugs, to patients affected by specific tumours identified by known cancer genetic markers as well as the genetic monitoring of the responsiveness of the patients to the treatments.

In addition to the cryopreservation of cord blood stem cells, Bioscience Institute operates in the promotion and support of projects in clinical and preclinical research. The main objective of this research is the discovery of new, safe and effective therapeutic applications for cell therapy products that the cell-factory is able to offer. For this reason Bioscience Institute collaborates with research groups of prestigious Italian universities and doctors of international repute. PRE-CLINICAL RESEARCH PROJECTS

  1. Determination of the effects of increasing platelet gel concentrations on the proliferation and differentiation of different cell populations. Platelet gel is a blood product with non trasfusional use containing several Platelet Derived Growth Factors that spread from the gel and support tissue repair. The therapeutic potential of platelet gel has been widely proved both in vitro and in vivo but there is a lack of conformity regarding the data reported in literature. This is probably due to the fact that platelet gel is used as a supplement to normal culture media, without considering the initial concentration of platelets/ul. We are therefore evaluating what are the optimal platelet gel concentrations able to induce the proliferation and/or differentiation of different cell populations: fibroblasts, keratinocytes and Adipose-Derived Stem Cells.
    ONGOING - University of Bologna

  2. Optimization of Adipose Derived Stem Cells isolation techniques. It has been shown how a good isolation rate and expansion ability of Adipose Derived Stem Cells in culture depends both on the technique used to collect the fat and the technique used to isolate the stem cells. In order to standardize and improve the quality and the ADSC isolation rate, we are evaluating different protocols that foresee the mechanical homogenization or the enzymatic digestion as first step to isolate the cells from the fat.
    ONGOING

  3. Evaluation of adult Adipose Derived Stem Cells multipotency and their ability to differentiate into cardiomyocytes or pericytes. ADSC can be widely used for different clinical applications in regenerative medicine as they are easily isolated from the fat, they can be collected from the patient himself, they have a good proliferative ability in vitro, they have low immunogenicity, they are able to integrate into the receiving tissue and interact with the surrounding tissues through paracrine mechanisms. Different studies have also shown that ADSC are able to differentiate into cell populations of the mesenchymal line (adipocytes, osteocytes, chondrocytes, smooth and skeletal muscle cells, heart muscle cells) but also into vascular endothelial cells, neurons, hepatocytes, pancreatic cells and hematopoietic cells. Thanks to their pluripotency, ADSC are frequently used to repair damaged tissues. The purpose of this project is to to evaluate the effects of the treatment with ADSC with physical stimulus combined to a cocktail of synthetic molecules able to increase the efficiency and reproducibility of their differentiation into cardiomyocytes or pericytes.
    ONGOING - University of Milan Bicocca

  4. Analysis of the mechanisms responsible for vitiligo. Vitiligo is a chronic condition that causes a loss of skin pigmentation, caused by an alteration into the amount and functionality of the melanocytes. The causes of this disorders are still unclear, there are different hypothesis: genetic, autoimmune, biochemical, and neuronal. It’s been shown how melanocytes took from non affected areas of the patients are more sensitive to oxidative stress, which is thus a possible marker for this disease. In order to prove this hypothesis, in vitro experiments on melanocytes isolated from healthy and vitiligo patients are being performed.
    ONGOING - Istituto Dermatologico San Gallicano Rome

  5. Evaluation of the secretory activity of Adipose Derived Stem Cells. Adipose tissue actively participates to the endocrine secretion through cytokines and growth factors secretion. Adipose Derived Stem Cells too are able to release growth factors and cytokines with angiogenetic and anti apoptotic properties. The purpose of this project is to analyze the molecules contained within the secretome released into the culture medium durig ADSC proliferation. ADSC are often used inside biodegradable scaffolds. The analysis of the secretome is also performed after the cells are seeded into a regular meshed polylactic scaffold to highlight possible variations and validate the scaffold system.
    ONGOING - University of Bologna

  6. Development of new scaffolds for tissue engineering applications. Any material used as a scaffold,has to be biocompatible, biodegradable, elastic and resistant.Silk fibroin has been used to realize bioresorbable skin substitutes made by a layer of fibroin and adult stem cells isolated from adipose tissue. Those layers showed good results for the obtention of engineered skin (Chlapanidas et al., AICC, 2010).

  7. Use of adult Adipose Derived Stem Cells for the inversion and or blocking of miniaturization process. The follicle can be considered as a mini organ characterized by growth cycles and loss of hair, that regrows thanks to the synergic activity of its pool of stem cells. Miniaturization is a degenerative process that progressively brings to the development of very short and thin hair with a reduction of the anagen phase and epithelial and mesenchymal compartments dimensions. It’s been recently discovered that ADSC are able to induce hair growth of immunosuppressed animals in vitro and in vivo. In this case, stem cells isolated from adipose tissue are tested for their ability to induce hair regeneration
    ONGOING

  8. Research of new active molecules for tissue regeneration in case of myocardial infarction. Hyaluronan mixed esters of butyric and retinoic acid (HBR) are able to induce cardiogenesis and vasculogenesis either in vitro in mesenchymal cells isolated from the dental pulp, spinal cord and placenta or in vivo, in infracted rats. Mesenchymal stem cells transplantation derived from the placenta and treated with HBR increase capillary density in heart, normalizes ventricular functionality and reduces scar tissue. From a molecular point of view, HBR induces the expression of Smad proteins that play a key-role in the cardiogenesis processes. Successive studies showed how the injection of HBR into infracted rat hearts afforded substantial cardiovascular repair and recover of myocardial performance thanks to the recruitment of Stro-1 stem cells into a pro-angiogenic paracrine circuitry of angiogenetic factors. These findings may pave new perspectives in clinical studies for myocardial regeneration, without the need of stem cell transplantation. (Ventura et al. JBC 2007; / Lionetti et al., JBC 2010; / Maioli et al., PlosONE 2010).

► CLINICAL RESEARCH PROJECTS

  1. Autologous adipose-derived stem cells for treatment of sistemic sclerosis.Systemic sclerosis is a rare heterogeneous disease, characterized by progressive accumulation of fibrotic tissue on skin and internal organs. Autologous adipose-derived stem cells (ADSC) were expanded in vitro and administered to 6 patients with systemic sclerosis. ADSC were injected as a suspension in a solution containing hyaluronic acid. This treatment determined a significant improvement in tightening of the skin without complications, suggesting that ADSC are a potentially valuable source of cells for skin therapy (Scuderi et al., Cell Transplantation, in press).

  2. Autologous adipose-derived stem cells for the regeneration of cutaneous tissue.Thanks to their pluripotency, adipose-derived stem cells (ADSC) are one of the most promising populations of mesenchimal stem cells for regenerative medicine applications. Autologous, in-vitro expanded ADSC are administered to patients with severe cutaneous defects, such as burns, or aesthetic alterations, as stretch marks or cutaneous laxities. After treatment, morphological and functional analysis are performed to evaluate cutaneous regeneration.
    ONGOING - University of Bologna

  3. Autologous in-vitro expanded keratinocytes for reconstruction of oral mucosa. Keratinocytes isolated from an oral mucosa biopsy are isolated and expanded in vitro till the formation of an epithelial patch. Patches are then applied to areas of the mouth where keratinized tissue is absent or incomplete.
    ONGOING - University of Milan

  4. Autologous in vitro-expanded keratinocytes for vaginal reconstruction in patients with Mayer-von Rokitansky-Kuster-Hauser syndrome. Mayer-von Rokitansky-Kuster-Hauser syndrome is characterized by vaginal agenesis. A 28 years old woman with this syndrome underwent a successful autologous vaginal tissue transplantation. The transplanted patch was composed by in vitro-expanded keratinocytes obtained from a full-thickness mucosal biopsy from the vaginal vestibule (Benedetti Panici et al., Human Reproduction 2007) (Benedetti Panici et al., Human Reproduction 2007).